ABSTRACT. Milk gangliosides inhibit Vibrio cholerae enterotoxin and Escherichia coli heat-labile enterotoxin. Human milk gangliosides showed considerably higher enterotoxin-inhibitory activity compared to bovine and formula milk gangliosides as measured in vitro by enzymelinked immunosorbent assay and in vivo in rabbit small bowel loops. While gangliosides from less than 1 ml human milk inhibited 0.1 pg choleratoxin in vitro and in vivo, five to 10 times higher amounts of bovine milk gangliosides were necessary to achieve similar results. Analysis of the ganglioside composition in human, bovine, and bovine milkbased formula milk showed that the ganglioside patterns in human and bovine milk differed markedly. The ganglioside patterns of bovine milk and formula milk appeared identical. In human or bovine milk, the total amount of gangliosides was 11 mgjliter compared to 6 mglliter in formula milk. The predominating ganglioside in human milk, monosialoganglioside 3 (74% of total gangliosides), was only a minor component (3%) of bovine milk gangliosides. Disialoganglioside 3 represented 80% of bovine milk gangliosides compared to 25% of the human milk gangliosides. Trace amounts of monosialoganglioside 1 were detected in human, as well as in bovine, milk by a sensitive high performance thin-layer chromatography immunoassay. The monosialoganglioside 1 content in human milk was 10 times higher than in bovine milk. We conclude that the higher nonimmunoglobulin enterotoxin-inhibitory activity in human milk compared to bovine milk is associated with the differences in the ganglioside fraction. (Pediatr Res 20: 416-421,1986) 
HPTLC, high performance thin-layer chromatography LT, Escherichia coli heat-labile enterotoxin mG, milk ganglioside PBS, phosphate-buffered saline Breast-fed infants are less susceptible to gastrointestinal infections compared to infants fed on cow's milk or formula milk (l-3). The protective potential of human milk may have its greatest impact in areas with poor hygiene and high exposure rates. In such areas, it has been shown that breast-feeding significantly reduces infant morbidity and mortality associated with diarrheal diseases (4) . However, it is also well documented that breast-fed infants in populations with higher living standards experience a lower rate of gastrointestinal illness than infants fed on cow's or formula milk (5) . Several of the factors in human milk which are considered to be of importance in the protection of the infant against bacterial disease (6) are found in markedly lower quantities in bovine milk. This applies especially to secretory IgA, lactofenin, lysozyme, and Lactobacillus bifidus growth factors (7) . ~, In previous reports byotnaess and coworkers (8) (9) (10) it has been reported that nonimmunoglobulin fractions from human milk inhibit LT and CT. We have previously demonstrated that this enterotoxin-inhibitory activity resides in the milk ganglioside fraction (1 1).
Gangliosides are glycosphingolipids which contain sialic acid and are mainly found in cell membranes. The ganglioside GM 1 is the cell membrane receptor for CT (12) (13) (14) , as well as for LT (15, 16 ). An additional receptor, a glycoprotein, may exist for LT (17) .
In milk, gangliosides are found mainly in the fat globule membranes (18, 19) which are derived from mammary gland cell membranes. In a study of bovine milk, six gangliosides were detected (19) of which three have been identified as GD3, GM2, and GM3 (19, 20) .
Preliminary studies indicated that bovine milk contained less enterotoxin-inhibitory activity than human milk (21, 22) . One likely explanation is that this is caused by a difference in the ganglioside composition. The purpose of the present study was to compare the ganglioside fractions from human and bovine milk with respect to ganglioside composition and enterotoxininhibitory activity. Antisera. Rabbit anti-CT was prepared as described (9 A. Vevey, Switzerland) was prepared according to the instructions of the producer. The human and bovine milk samples were stored at -20" C. Milk fat was obtained by centrifugation (human milk: 35,000 x g, 20 min; bovine milk: 15,000 x g, 1 h; formula milk: 9,400 x g, 2 h; 4" C). The fat yield from human milk was 62 g/liter wet weight. From bovine and formula milk 60 and 50 g milk fatlliter, respectively, were obtained.
MATERIALS AND METHODS

Materials
Ganglioside isolation and analysis. HPTLC was performed using silica gel 60 HPTLC precoated plates (glassplates 10 X 10 cm, or aluminum sheets; Merck). The plates were activated at 100" C and developed in chloroform/ methanol/0.25% CaC12 in water (60:35:8). For visualization of components, the plates were sprayed with resorcinol (24) or anaphtol/sulfuric acid (25) and incubated at 100" C for color development. Plates sprayed with resorcinol were covered with a clean glassplate during heating. Densitometry of HPTLC-plates was performed with a Shimadzu Dual-Wavelength TLC-Scanner CS-930. The chromatograms were obtained by single wavelength zig-zag scanning of each HPTLC-lane at 580 nm (beam dimension: 0.4 x 0.4 mm) in the reflection mode.
Small amounts of GM1 were detected by use of an HPTLCimmunoassay (Kolstg Otnzss AB, Lzgreid A, manuscript in preparation). GM 1 was visualized by the successive incubation of the aluminum sheet HPTLC-plate in aqueous solutions containing i) native, freshly diluted CT, ii) rabbit anti-CT, and iii) ('251)monoclonal anti-rabbit IgG followed by autoradiography. Amounts of less than 0.01 ng (0.0065 pmol) GMl could be detected by this method.
Measurement of enterotoxin-inhibitory activity. The enterotoxin-inhibitory activity of milk ganglioside preparations was assayed in vitro by an ELISA test measuring the reduction of binding of CT to polyvinyl microtiterplates (Dynatec Laboratories Ltd., Sussex, England) coated with GMl (26). The ELISA was performed essentially as described previously (1 1), employing purified CT instead of LT. Briefly, the milk gangliosides, dissolved in PBS, were incubated with equal volumes of a CTsolution (0.1 pg/ml) before application to the microtiterplate. The microtiterplate was incubated 1 h at 37" C, followed by the successive incubation with rabbit anti-CT and sheep anti-rabbit IgG conjugated to alkaline phosphatase (27) . The amount of bound CT in each well was measured spectrophotometrically as color development of enzyme substrate. A standard curve for CT (0.001-0.1 pg/ml) mixed with equal volumes of PBS was included on each microtiterplate. The in vivo enterotoxin-inhibitory activity was assayed in a rabbit small bowel loop assay (28) as described (1 1). CT with or without milk gangliosides in a total volume of 1 ml was injected into each of 20-25 small bowel loops in New Zealand White male rabbits (1 3-2.4 kg) anaesthetized with pentobarbituratum (25-40 mg/kg). The animals were sacrificed after 19-20 h and the volume and length of each loop were measured. In each animal, two dose-response curves were obtained for CT mixed with buffer. Milk ganglioside preparations were tested with three different CT concentrations each.
RESULTS
Composition ofthe milk fat gangliosidepreparations. The main
human milk gangliosides, hmGI, hmGII, and hmGIII (1 l), showed similar migration on HPTLC-plates as three of the bovine milk gangliosides (Fig. IA) . These bovine milk gangliosides were designated bmGI-111. Two additional gangliosides, designated bmGIV and bmGV, were detected in the preparations from bovine and formula milk fat (Fig. 1A) . The amounts of the individual milk gangliosides (Table 1 ) were calculated from densitometric measurements of two parallel HPTLC-experiments with reference to standard curves for GM 1. The standard curves were obtained by the inclusion of purified GM1 (0.05-3.0 pg) on each HPTLC-plate. Variation between the two HPTLC-plates was 10-20%. The recovery of gangliosides in the crude ganglioside preparation after protein precipitation and dialysis was 50% (28a) and the data in Table 1 were corrected accordingly, i.e. the measured values have been multiplied by a factor of 2 in order to obtain values representative for whole milk.
While the ganglioside pattern in bovine and formula milk was very similar, the relative amounts of the milk gangliosides I, 11, and 111 were entirely different in human and bovine milk (Fig.  1B and Table 1 ). The total ganglioside content in human and bovine milk fat seemed to be equal, while considerably less quantities of gangliosides were found in formula milk (Table 1) .
Although GM 1 was not detectable by staining with resorcinol or a naphtol (Fig. 1A and Fig. 2B ), this ganglioside was demonstrated in the human, as well as in the bovine and formula, milk ganglioside preparations by an immunoassay of HPTLCplates ( Fig. 2A) . The amount of GM 1 derived from 1 g of human milk fat was 0.1 pg (mean value; range 0.07-1.5 pg) while the corresponding values for bovine and formula milk fat were 0.0 1 pg (mean value; range 0.005-0.015 pg) and less than 0.01 pg, respectively. These results were based on seven independent experiments.
Enterotoxin-inhibitory activity of the milk fat gangliosidepreparations. In vitro, measured by ELISA, the human milk ganglioside preparations showed significantly higher inhibitory activity against CT than the ganglioside preparations from bovine and formula milk (Fig. 3) . Human milk gangliosides from 0.5 g fat per ml resulted in 100% inhibition, and the enterotoxin-inhibitory activity was still close to 50% on 10-fold dilution (Fig. 3) . However, in the case of bovine or formula milk, gangliosides from 1 g milk fat per ml were necessary for 100% enterotoxininhibition (data not shown) and inhibitory activity was more quickly lost on dilution (Fig. 3) .
Higher enterotoxin-inhibitory activity of human, as compared to bovine, milk gangliosides was also found in the in vivo assay.
Whereas human milk gangliosides from 0.5 g fafprevented fluid accumulation in rabbit small bowel loops at all CT-concentrations tested, bovine and formula milk gangliosides from 0.5 g milk fat showed practically no enterotoxin-inhibitory activity (Fig. 4) . Human milk gangliosides still showed high in vivo inhibitory activity when the amount was reduced to 0.1 g milk fat (Fig. 5A) . Bovine milk gangliosides from 1.0 g milk fat had to be applied to achieve enterotoxin-inhibitory activity similar to human milk gangliosides from 0.1 g fat (Fig. 5B) . Although each of the graphs in Figures 4, 5A, and 5B was based on data obtained from a single animal, similar differences between human and bovine milk gangliosides were found in the four animals tested. In the present study, it was shown that the relative amount of individual gangliosides in human milk fat differed markedly from that in bovine milk fat. Still, the total content of gangliosides was similar in human and bovine milk fat, and milk from the two species seemed to have several gangliosides in common. A comparison of the ganglioside pattern of human and bovine milk has not been previously published.
Ganglioside I from human and bovine milk (hmGI and bmGI) showed identical HPTLC-mobility with bovine brain GD3 (Fig.  1A and Fig. 2B ). GD3 has previously been identified as the most abundant ganglioside in bovine milk (19, 20) , and our findings are in agreement with these data. Although preliminary gas chromatographic analysis of hmGI indicated that the sugar composition of hmGI was different from that of GD3 (29), further studies, using highly purified hmG1-preparations, showed that hmGI was identical with GD3 (Lagreid A, Kolstfl Otnass A-B, Bryn X, manuscript submitted). The human milk ganglioside hmGIII is identical with GM3 (29; Lagreid A, Kolst$ Otnzss A-B, Bryn X, manuscript submitted). Since the bovine milk ganglioside bmGIII migrated similarly to hmGIII (GM3) on HPTLC, it is likely that bmGIII was GM3 which has also been identified in bovine milk (19, 20) . The milk gangliosides hmGII and bmGII migrated in the area of GM2 and may both be identical with GM2 known to be present in bovine milk (19, 20) . * mGI-mGV were calculated from densitometric measurements of HPTLC-plates stained with resorcinol. GM1 was calculated from immunoassay of HPTLC-plates.
as in bovine, milk. The presence of G M l in human milk'has not previously been reported, and due to its low abundancy G M l was not detected in an earlier study of bovine milk gangliosides (1 9). GM 1 was identified by i) the binding of CT, a ligand which is highly specific for GMl (30) and by ii) the identical HPTLCmobility of the CT-binding milk ganglioside with that of purified bovine brain GM 1 (Fig. 2) . Since Enterotoxin-inhibitory activity of human, bovine, and formula milk gangliosides measured in ELISA as the reduction of binding of CT to GMI-coated microtiter-plates. Values are means of four independent experiments, and each sample was tested in duplicate. SE was within 5-10%; for human milk gangliosides at 0.5 g milk fat per ml SE was less than 1%. Differences between human milk and bovine and formula milk gangliosides are statistically significant by the t test ( p < 0.001). chromatograms was only possible by radioimmunological visualization of GM 1-bound CT. By this method, the sensitivity was increased more than 1000-fold compared to resorcinol staining, with the concurrent advantage of high specificity for GM 1.
Ch
Thus, the gangliosides found in both human and bovine milk were GD3, GMI, GM3, and possibly GM2. The gangliosides bmGIV and bmGV were detected in bovine milk only. While the most abundant ganglioside in human milk was GM3, representing 74% of total gangliosides, this ganglioside was only a minor component (3%) of the bovine milk gangliosides (Table  I) . GD3 amounted to 80% of total bovine milk gangliosides compared to 25% of human milk gangliosides (Table I) . After completion of this work, Hauttecoeur et al. (31) published an analysis of GD3 from bovine buttermilk. GD3 represented 85% of total lipid-bound sialic acid in buttermilk which is in agreement with our data. The milk ganglioside, designated mGII (which may be GM2), was a minor ganglioside component in both human and bovine milk, representing 2 and 6%, respectively, of total milk gangliosides ( Table 1 ). The composition of formula milk gangliosides, on which no analysis has been reported earlier, appeared identicaj with the unprocessed bovine milk gangliosides except for the lower quantities of bmGIII in formula milk (Fig. I B and Table 1 ). The fact that such high correlation was found between the ganglioside patterns of two different preparations of bovine milk, i.e. fresh bovine milk and bovine milk-based formula milk, emphasizes the significance of the differences between human and bovine milk ganglioside patterns observed in this study.
The present study extends our preliminary data on the difference between nonimmunoglobulin enterotoxin-inhibitory activity of human, compared to bovine and formula, milk (22) . Human milk gangliosides from 0.1 g fat, corresponding to 0.8 ml whole milk, inhibited 70% of the binding of 0.1 pg CT in vitro, while the same amount of gangliosides completely inhibited fluid accumulation in rabbit ileal loops induced by 0.1 pg CT. These results are in agreement with data obtained by measurements of the enterotoxin-inhibitory activity of gangliosides from a different pool of human milk in a previous study (1 1). In comparison, five to 10 times higher amounts of bovine or formula milk gangliosides were necessary to achieve similar enterotoxin inhibition. The inhibitory activity in human milk gangliosides might be physiologically relevant since Vibrio cholerae in culture produces much less than 1 pg CT per ml (32) , and the concentration of CT in stools from cholera patients has been reported to be in the range of from less than 0.001 to 0.15 pgIml (33) .
Similar to a previous study (1 l), there was good agreement between enterotoxin-inhibitory activities measured in vivo in rabbit intestines and in vitro by the ELISA method as similar differences between the human and bovine milk gangliosides preparations were found by both methods.
In a previous study, the enterotoxin-inhibitory activity of the human milk ganglioside preparation was eluted from TLC in an area where GM 1 and hmGI migrated (1 1). Since by HPTLC no GM I was detected in a preparation of hmGI, although considerable toxin-inhibitory activity was measured (29), we concluded that the toxin-inhibitory was most likely due to hmGI rather than GM1. However, when the 1000-fold more sensitive HPTLC-immunoassay for GM1 was employed, GM1 was detected in the hmGI-preparation (Laegreid A, Kolsta O t n~s s A-B, manuscript in preparation). Upon separation of human milk gangliosides, the inhibitory activity was found only in fractions which contained GMI while highly purified preparations of hmGI and hmGIII which were devoid of GMI showed no enterotoxin-inhibitory activity (L~greid A, Kolsta Otnzss A-B, manuscript in preparation).
Thus the trace amounts of GM1 present in human, as well as in bovine, milk were most likely responsible for the enterotoxininhibitory activity in the ganglioside fractions. Compared to human milk gangliosides, five to 10 times more of the bovine milk gangliosides had to be applied to achieve a similar inhibition of CT. This correlated well with the finding of one-tenth the amount of GM1 in bovine milk fat compared to human milk fat.
The inhibitory activity against LT was not measured in this study. However, earlier studies have shown that LT and CT are inhibited to a similar extent by nonimmunoglobulin human milk fractions (10, 11) . In addition to GMI, which probably prevents binding of enterotoxins to intestinal cells, human milk may contain receptor-like glycocompounds which can prevent adherence of V. cholerae and Escherichia coli (34, 35) . The presence in human milk of secretory IgA against V. cholerae and E. coli enterotoxins (36) and against bacterial membrane antigens (37,38) most likely plays the most important role in the protection of infants against diarrhea following bacterial infection, as suggested by a field study in a cholera endemic area (38) . The antidiarrheal potential of human milk has also been demonstrated by the interruption of E. coli diarrhea with small quantities of human colostrum ( 5 ml/kg/day) (39), as well as by the successful treatment of protracted diarrhea by feeding affected infants with mature milk (40) .
The demonstration that GM1 is a nonimmunoglobulin component contributing to the enterotoxin-inhibitory activity of human milk (~e~r e i d A, Kolsta Otnaess A-B, manuscript in preparation) indicates that compounds present in trace amounts only may play a significant role in the "second line of defense" against infection when a high level of specific antibodies is lacking. The present study shows that bovine and formula milk contain significantly lower levels of GM1 compared to human milk and that the lower levels of GMI are associated with markedly lower enterotoxin-inhibitory activity in bovine and formula milk.
